Clinical Trials Logo

Advanced Gastric Carcinoma clinical trials

View clinical trials related to Advanced Gastric Carcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05351398 Not yet recruiting - Clinical trials for Advanced Gastric Carcinoma

The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid Versus Traditional Neoadjuvant Chemotherapy in Advanced Gastric Cancer

Start date: April 2022
Phase:
Study type: Observational

Neoadjuvant chemotherapy has become the mainstream recommended treatment for advanced gastric cancer. However, due to the heterogeneity of gastric cancer, part of some patients fail to benefit from the treatment. This project aims to compare the clinical efficacy of individualized neoadjuvant therapy based on patient-derived organoid drug sensitivity assay and traditional regimen, exploring the advantages and disadvantages of these two treatments. And access the safety and clinical value of the personalized neoadjuvant therapy based on patient-derived organoid drug sensitivity assay in advanced gastric cancer.

NCT ID: NCT05313906 Not yet recruiting - Clinical trials for HER2-positive Gastric Cancer

RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer

Start date: May 7, 2022
Phase: Phase 2
Study type: Interventional

To explore the safety and clinical efficacy of cisplatin combined with RC48 and anti-PD-1 antibodies AK105 in Her-2 positive advanced gastric cancer.

NCT ID: NCT05270824 Not yet recruiting - Clinical trials for Advanced Gastric Carcinoma

Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma

Start date: March 1, 2022
Phase: Phase 3
Study type: Interventional

Focusing on the clinical question of whether patients with advanced gastric cancer can benefit from immunotherapy, this project intends to detect the degree of CD8+ tumor-infiltrating lymphocyte infiltration in patients with advanced gastric cancer before and after receiving neoadjuvant combined immunotherapy and neoadjuvant therapy alone. To explore the evolving nature of tumor immune response before and after neoadjuvant therapy for gastric cancer, and quantitatively present it through chemical immunohistochemical techniques to achieve a more accurate diagnosis and treatment and improve the long-term efficacy of patients.

NCT ID: NCT02163291 Not yet recruiting - Clinical trials for Advanced Gastric Carcinoma

Study on Neoadjuvant Chemotherapy for Advanced Gastric Cancer

Start date: December 2013
Phase: Phase 2
Study type: Interventional

Gastric cancer is the second cause of cancer related death and China has the most gastric cancer patients in the world. Although systemic strategies, including adjuvant chemotherapy, postoperative chemoradiotherapy, perioperative chemotherapy, have evolved and showed benefits these years, the prognosis of advanced gastric cancer is still not satisfactory. Optimal regimens and optimal method administration is still being found. Neoadjuvant chemotherapy has many advantages, including downstaging the tumor, increasing R0 rate, early eradicating of micrometastasis. In previous trials, combination of paclitaxel and s-1 has showed safety and tolerance in recurrent or metastatic gastric cancer. Using liposome as a carrier, paclitaxel has a better histocompatibility and cellular affinity, resulting a improved stability and reduced toxicity. In this phase II trial, we are going to study the safety and feasibility of paclitaxel liposome plus s-1 as neoadjuvant chemotherapy.